Swiss National Bank
RIGL icon

Swiss National Bank’s Rigel Pharmaceuticals RIGL Stock Holding History

Swiss National Bank’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-40,438
Closed -$477K – 2716
2022
Q3 		$477K Hold
40,438
– – ﹤0.01% 2587
2022
Q2 		$457K Hold
40,438
– – ﹤0.01% 2633
2022
Q1 		$1.21M Buy
40,438
+3,190
+9% +$86.4K ﹤0.01% 2312
2021
Q4 		$987K Hold
37,248
– – ﹤0.01% 2484
2021
Q3 		$1.35M Hold
37,248
– – ﹤0.01% 2282
2021
Q2 		$1.62M Sell
37,248
-1,020
-3% -$38.5K ﹤0.01% 2241
2021
Q1 		$1.31M Hold
38,268
– – ﹤0.01% 2237
2020
Q4 		$1.34M Hold
38,268
– – ﹤0.01% 2146
2020
Q3 		$918K Hold
38,268
– – ﹤0.01% 2126
2020
Q2 		$700K Buy
38,268
+6,190
+19% +$111K ﹤0.01% 2285
2020
Q1 		$500K Hold
32,078
– – ﹤0.01% 2178
2019
Q4 		$686K Buy
32,078
+1,070
+3% +$22K ﹤0.01% 2311
2019
Q3 		$580K Hold
31,008
– – ﹤0.01% 2309
2019
Q2 		$809K Buy
31,008
+3,050
+11% +$68.8K ﹤0.01% 2230
2019
Q1 		$719K Hold
27,958
– – ﹤0.01% 2250
2018
Q4 		$643K Buy
27,958
+840
+3% +$23.7K ﹤0.01% 2240
2018
Q3 		$870K Hold
27,118
– – ﹤0.01% 2220
2018
Q2 		$767K Buy
27,118
+4,158
+18% +$148K ﹤0.01% 2310
2018
Q1 		$813K Hold
22,960
– – ﹤0.01% 2190
2017
Q4 		$891K Buy
+22,960
New +$874K ﹤0.01% 2155
2014
Q4 		– Sell
-9,160
Closed -$178K – 2579
2014
Q3 		$178K Hold
9,160
– – ﹤0.01% 2455
2014
Q2 		$333K Sell
9,160
-1,090
-11% -$37.1K ﹤0.01% 2350
2014
Q1 		$398K Buy
10,250
+2,700
+36% +$96.3K ﹤0.01% 2225
2013
Q4 		$215K Hold
7,550
– – ﹤0.01% 2377
2013
Q3 		$270K Sell
7,550
-700
-8% -$25.5K ﹤0.01% 2265
2013
Q2 		$276K Buy
+8,250
New +$374K ﹤0.01% 2253

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank's RIGL Position: Q4 2022 in Review

Swiss National Bank sold out of Rigel Pharmaceuticals (RIGL) in Q4 2022, closing a stake of 40,438 shares — an estimated $477K sold.

Swiss National Bank first reported a position in RIGL in Q2 2013 and held it in 26 quarters. The position peaked at $1.62M in Q2 2021. 118 funds tracked by Wall St. Rank hold RIGL as of Q4 2022.

  • Swiss National Bank reported no remaining Rigel Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Swiss National Bank sold 40,438 Rigel Pharmaceuticals shares in Q4 2022, an estimated $477K.
  • Swiss National Bank first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 26 quarters.
  • Swiss National Bank's Rigel Pharmaceuticals position peaked at $1.62M in Q2 2021.
  • 118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2022.

Based on Swiss National Bank's 13F filing for Q4 2022, filed 8 Feb 2023.